Total Payments
$945,674
2024 Payments
$102,602
Companies
49
Transactions
566
Medicare Patients
6,869
Medicare Billing
$1.1M
Payment Breakdown by Category
Consulting$507,003 (53.6%)
Travel$164,774 (17.4%)
Research$102,418 (10.8%)
Other$94,265 (10.0%)
Education$68,618 (7.3%)
Food & Beverage$8,596 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $507,003 | 132 | 53.6% |
| Travel and Lodging | $164,774 | 161 | 17.4% |
| Unspecified | $102,418 | 12 | 10.8% |
| Education | $68,618 | 62 | 7.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $57,595 | 32 | 6.1% |
| Grant | $29,820 | 2 | 3.2% |
| Food and Beverage | $8,596 | 162 | 0.9% |
| Honoraria | $6,850 | 3 | 0.7% |
Payments by Type
General
$843,256
554 transactions
Research
$102,418
12 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $256,491 | 148 | $0 (2024) |
| AstraZeneca UK Limited | $106,894 | 34 | $0 (2020) |
| Pulmonx Corporation | $89,428 | 40 | $0 (2024) |
| Olympus Corporation of the Americas | $70,442 | 108 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $64,719 | 28 | $0 (2024) |
| Fisher & Paykel Healthcare Limited | $56,729 | 11 | $0 (2023) |
| Eli Lilly and Company | $43,368 | 5 | $0 (2021) |
| PneumRx, Inc | $40,104 | 7 | $0 (2018) |
| Spiration, Inc. | $37,562 | 36 | $0 (2019) |
| GENZYME CORPORATION | $30,210 | 16 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $102,602 | 59 | GENZYME CORPORATION ($26,200) |
| 2023 | $58,889 | 30 | Pulmonx Corporation ($21,834) |
| 2022 | $39,598 | 30 | Philips Electronics North America Corporation ($14,544) |
| 2021 | $109,210 | 63 | Eli Lilly and Company ($34,479) |
| 2020 | $73,015 | 45 | Boehringer Ingelheim Pharmaceuticals, Inc. ($15,721) |
| 2019 | $209,013 | 141 | AstraZeneca UK Limited ($76,805) |
| 2018 | $218,964 | 129 | GlaxoSmithKline, LLC. ($100,812) |
| 2017 | $134,383 | 69 | GlaxoSmithKline, LLC. ($72,053) |
All Payment Transactions
566 individual payment records from CMS Open Payments — Page 1 of 23
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $8,775.00 | General |
| 12/23/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,953.50 | General |
| 12/07/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | Cash or cash equivalent | $120.00 | General |
| 11/12/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $118.08 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/12/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $33.11 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/05/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $2,600.00 | General |
| 10/07/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $62.85 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/07/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $68.84 | General |
| Category: Immunology | ||||||
| 09/04/2024 | Pulmonx Corporation | ZEPHYR ENDOBRONCHIAL VALVE (Device) | Grant | Cash or cash equivalent | $22,620.00 | General |
| Category: PULMONOLOGY | ||||||
| 08/30/2024 | Pulmonx Corporation | ZEPHYR ENDOBRONCHIAL VALVE (Device) | Food and Beverage | Cash or cash equivalent | $45.87 | General |
| Category: PULMONOLOGY | ||||||
| 08/22/2024 | GENZYME CORPORATION | — | Travel and Lodging | Cash or cash equivalent | $56.00 | General |
| 08/21/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $11,325.00 | General |
| 08/16/2024 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $572.75 | General |
| 08/16/2024 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $292.67 | General |
| 08/09/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | SPIRIVA RESPIMAT (Drug) | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| Category: RESPIRATORY | ||||||
| 07/30/2024 | Philips North America LLC | (6691) HRC Undivided (Device) | — | Cash or cash equivalent | $5,382.58 | Research |
| Study: SRC-HRC-VectorEfficacy-2018-10377 • Category: Medical Device | ||||||
| 07/03/2024 | Pulmonx Corporation | ZEPHYR ENDOBRONCHIAL VALVE (Device) | Food and Beverage | Cash or cash equivalent | $62.40 | General |
| Category: PULMONOLOGY | ||||||
| 06/22/2024 | Genentech USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $5,115.00 | General |
| 06/22/2024 | Genentech USA, Inc. | — | Travel and Lodging | In-kind items and services | $415.45 | General |
| 06/22/2024 | Genentech USA, Inc. | — | Travel and Lodging | In-kind items and services | $245.18 | General |
| 06/22/2024 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $12.74 | General |
| 06/22/2024 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $7.46 | General |
| 06/17/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $3,900.00 | General |
| 06/12/2024 | Olympus Corporation of the Americas | SPiN Vision Video Processor (Device) | Education | Cash or cash equivalent | $3,740.00 | General |
| Category: Respiratory | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, SPONSOR UNBLINDED, SINGLE ASCENDING DOSE, PHASE 1 FIRST IN HUMAN STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVENOUS LY3819253 IN PARTICIPANTS HOSPITALIZED FOR COVID 19 | Eli Lilly and Company | $28,848 | 2 |
| myAIRVO | Fisher & Paykel Healthcare Limited | $16,840 | 1 |
| Tolerance and Acute effects of HFNC-O2 | Fisher & Paykel Healthcare Limited | $16,250 | 1 |
| SRC-HRC-VectorEfficacy-2018-10377 | Philips Electronics North America Corporation | $14,544 | 1 |
| A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | Eli Lilly and Company | $14,520 | 3 |
| SRC-HRC-VectorEfficacy-2018-10377 | Philips North America LLC | $5,383 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH RESEARCH AGREEMENT | Novartis Pharmaceuticals Corporation | $3,281 | 1 |
| AN ADAPTIVE PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING EFFICACY AND SAFETY OF SARILUMAB FOR HOSPITALIZED PATIENTS WITH COVID-19 | Regeneron Pharmaceuticals, Inc. | $1,518 | 1 |
| LINQ COPD | Medtronic, Inc. | $1,235 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 21 | 1,333 | 2,157 | $487,315 | $190,986 |
| 2022 | 24 | 1,568 | 2,537 | $550,470 | $213,174 |
| 2021 | 22 | 1,834 | 4,720 | $762,749 | $305,982 |
| 2020 | 27 | 2,134 | 10,750 | $980,250 | $401,975 |
Total Patients
6,869
Total Services
20,164
Medicare Billing
$1.1M
Procedure Codes
110
All Medicare Procedures & Services
110 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 147 | 312 | $81,120 | $35,339 | 43.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 197 | 328 | $65,600 | $33,438 | 51.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 279 | 429 | $85,800 | $33,097 | 38.6% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 53 | 111 | $67,710 | $19,786 | 29.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 72 | 117 | $30,420 | $16,762 | 55.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 54 | 144 | $20,160 | $9,291 | 46.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 84 | 84 | $25,320 | $8,889 | 35.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 56 | 56 | $16,800 | $7,330 | 43.6% |
| 31622 | Diagnostic exam of lung airway using an endoscope | Facility | 2023 | 32 | 67 | $29,480 | $6,817 | 23.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 28 | 53 | $10,600 | $5,268 | 49.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 36 | 41 | $6,560 | $2,772 | 42.3% |
| 31647 | Assessment of initial lobe of lung for air leak and airway sizing with insertion of bronchial valve in lung airway using an endoscope | Facility | 2023 | 16 | 17 | $11,900 | $2,732 | 23.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 12 | 131 | $6,550 | $1,567 | 23.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 11 | 11 | $4,895 | $1,514 | 30.9% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 17 | 17 | $1,700 | $1,223 | 71.9% |
| 31624 | Irrigation and suction of lung airways to obtain cells using an endoscope | Facility | 2023 | 15 | 15 | $6,750 | $1,114 | 16.5% |
| 31627 | Computer-assisted image-guided navigation of lung airways using an endoscope | Facility | 2023 | 14 | 14 | $4,480 | $1,108 | 24.7% |
| 94618 | Test for exercise-induced lung stress | Facility | 2023 | 40 | 40 | $3,200 | $730.80 | 22.8% |
| 31654 | Exam of lung airways with diagnostic or therapeutic procedure on growths using an endoscope and ultrasound | Facility | 2023 | 11 | 11 | $2,530 | $602.25 | 23.8% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 15 | 15 | $600.00 | $480.75 | 80.1% |
| 94010 | Test to measure expiratory airflow and volume | Facility | 2023 | 48 | 48 | $1,440 | $324.96 | 22.6% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2023 | 41 | 41 | $1,230 | $300.12 | 24.4% |
| 94726 | Test to determine lung volumes using sensors | Facility | 2023 | 28 | 28 | $1,120 | $275.24 | 24.6% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2023 | 27 | 27 | $1,350 | $227.88 | 16.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 213 | 380 | $98,800 | $45,584 | 46.1% |
About Dr. Gerard Criner, MD
Dr. Gerard Criner, MD is a Pulmonary Disease healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/12/2005. The National Provider Identifier (NPI) number assigned to this provider is 1013905157.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gerard Criner, MD has received a total of $945,674 in payments from pharmaceutical and medical device companies, with $102,602 received in 2024. These payments were reported across 566 transactions from 49 companies. The most common payment nature is "Consulting Fee" ($507,003).
As a Medicare-enrolled provider, Criner has provided services to 6,869 Medicare beneficiaries, totaling 20,164 services with total Medicare billing of $1.1M. Data is available for 4 years (2020–2023), covering 110 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Philadelphia, PA
- Active Since 10/12/2005
- Last Updated 05/12/2016
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1013905157
Products in Payments
- FASENRA (Drug) $95,859
- Spiration Valve System (Device) $74,485
- ZEPHYR ENDOBRONCHIAL VALVE (Device) $47,623
- PNEUMRX COILS (Device) $40,182
- myAIRVO (Device) $33,090
- Pulmonx Endobronchial Valve EBV (Device) $31,625
- STIOLTO RESPIMAT (Drug) $22,292
- (6691) HRC Undivided (Device) $19,926
- FISHER & PAYKEL HEALTHCARE (Device) $17,718
- Olympus Bronchoscopes (Device) $16,750
- OFEV (Drug) $16,576
- Olympus Capital Accessories (Device) $12,869
- Olympus Respiratory Accessories (Device) $12,213
- DUPIXENT (Biological) $11,097
- Veklury (Drug) $10,500
- CHARTIS CATHETER (Device) $10,180
- STIOLTO (Drug) $9,452
- VORAXAZE (Drug) $8,988
- Da Vinci Surgical System (Device) $7,847
- QVA149A (Drug) $7,367
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Philadelphia
Jeffrey Edelson, M.d, M.D
Pulmonary Disease — Payments: $437,125
Pulmonary Disease $437,125
Steven Geller, Do, DO
Pulmonary Disease — Payments: $251,222
Pulmonary Disease $251,222
Parth Rali, Md, MD
Pulmonary Disease — Payments: $232,570
Pulmonary Disease $232,570
Boyd Hehn, Md, MD
Pulmonary Disease — Payments: $139,719
Pulmonary Disease $139,719
Edward Schulman, Md, MD
Pulmonary Disease — Payments: $132,370
Pulmonary Disease $132,370
Gary Aaronson, Do, DO
Pulmonary Disease — Payments: $127,540
Pulmonary Disease $127,540